Last Updated: November 18, 2026

CLINICAL TRIALS PROFILE FOR RASAGILINE

« Back to Dashboard


505(b)(2) Clinical Trials for RASAGILINE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT00640159 ↗ Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease Completed Baylor College of Medicine Phase 4 2007-01-01 Parkinson's disease (PD) is a progressive neurodegenerative disease. Symptomatic therapy is primarily aimed at restoring dopamine function in the brain. Oral selegiline in conjunction with L-dopa has been a mainstay of therapy for PD patients experiencing motor fluctuations for many years. The mechanisms accounting for selegiline's beneficial adjunctive action in the treatment of PD are not fully understood. Inhibition of monoamine oxidase (MAO) type B (MAO-B) activity is generally considered to be of primary importance. Oral selegiline has low bio-availability and is typically dosed BID, for a total of 5-10 mg daily. Recently, the FDA approved a new orally disintegration tablet (ODT) formulation of selegiline, called ZelaparTM. This new formulation utilizes Zydis technology to dissolve in the mouth, with absorption through the oral mucosa, thereby largely bypassing the gut and avoiding first pass hepatic metabolism. This allows more active drug to be delivered at a lower dose. Consequently, Zelapar is dosed once-daily, up to 2.5 mg per day. There are no empirical data indicating whether the use of the new approved formulation of selegiline ODT (Zelapar) is superior or preferred by patients compared to traditional oral selegiline. It is believed that clinical efficacy will be preserved or enhanced, by delivering more active drug, with improved patient preference for the ODT formulation due to the once-daily dosing . The effectiveness of orally disintegrating selegiline as an adjunct to carbidopa/levodopa in the treatment of PD was established in a multicenter randomized placebo-controlled trial (n=140; 94 received orally disintegrating selegiline, 46 received placebo) of three months' duration. Patients randomized to orally disintegrating selegiline received a daily dose of 1.25 mg for the first 6 weeks and a daily dose of 2.5 mg for the last 6 weeks. Patients were all treated with levodopa and could additionally have been on dopamine agonists, anticholinergics, amantadine, or any combination of these during the trial. At 12 weeks, orally disintegrating selegiline-treated patients had an average of 2.2 hours per day less "OFF" time compared to baseline. Placebo treated patients had 0.6 hours per day less "OFF" time compared to baseline. These differences were significant (p < 0.001). Adverse events were very similar between drug and placebo.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for RASAGILINE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00104273 ↗ Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) Completed Eisai Inc. Phase 2 2004-08-01 The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
NCT00104273 ↗ Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) Completed Teva Branded Pharmaceutical Products R&D, Inc. Phase 2 2004-08-01 The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
NCT00104273 ↗ Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) Completed Teva Pharmaceutical Industries Phase 2 2004-08-01 The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
NCT00203034 ↗ Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations Completed Teva Branded Pharmaceutical Products R&D, Inc. Phase 3 2000-05-01 Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for RASAGILINE

Condition Name

Condition Name for RASAGILINE
Intervention Trials
Parkinson's Disease 31
Parkinson Disease 7
Alzheimer's Disease 2
Amyotrophic Lateral Sclerosis (ALS) 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for RASAGILINE
Intervention Trials
Parkinson Disease 45
Sclerosis 3
Motor Neuron Disease 3
Amyotrophic Lateral Sclerosis 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for RASAGILINE

Trials by Country

Trials by Country for RASAGILINE
Location Trials
United States 234
Germany 27
Canada 15
Spain 8
Israel 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for RASAGILINE
Location Trials
California 16
New York 13
Florida 12
Texas 12
Illinois 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for RASAGILINE

Clinical Trial Phase

Clinical Trial Phase for RASAGILINE
Clinical Trial Phase Trials
PHASE4 1
PHASE1 1
Phase 4 19
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for RASAGILINE
Clinical Trial Phase Trials
Completed 40
Terminated 6
Unknown status 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for RASAGILINE

Sponsor Name

Sponsor Name for RASAGILINE
Sponsor Trials
Teva Branded Pharmaceutical Products R&D, Inc. 17
Teva Pharmaceutical Industries 16
H. Lundbeck A/S 10
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for RASAGILINE
Sponsor Trials
Other 67
Industry 64
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Rasagiline Clinical Trials, Market Analysis, Patent Status and 2025-2030 Projection

Last updated: August 1, 2026

Rasagiline is an oral monoamine oxidase-B inhibitor approved for Parkinson's disease as monotherapy in early disease and as adjunctive therapy to levodopa in more advanced disease. Its clinical value is established for symptomatic control, but disease-modifying claims were not confirmed in the ADAGIO trial. The U.S. market is generic, with limited pricing power and low barriers to substitution. Commercial opportunity is concentrated in cost-sensitive markets, fixed-dose combinations, specialty distribution, and development programs that use rasagiline as a comparator or combination component.

What is rasagiline approved to treat?

Rasagiline, marketed as Azilect by Teva Pharmaceuticals and historically developed by Teva and Lundbeck, is approved for Parkinson's disease.

Attribute Details
Active ingredient Rasagiline mesylate
Pharmacologic class Selective monoamine oxidase-B inhibitor
U.S. brand Azilect
U.S. approval May 16, 2006
Initial indication Monotherapy for Parkinson's disease
Expanded indication Adjunct to levodopa in patients with motor fluctuations
Dosage strengths 0.5 mg and 1 mg tablets
Standard adjunctive dose 1 mg once daily
FDA pathway New drug application
Primary therapeutic competitors Selegiline, safinamide, dopamine agonists, levodopa formulations
Current U.S. market structure Generic-dominated

The FDA approved rasagiline as monotherapy based on trials in patients with early Parkinson's disease and later approved adjunctive use with levodopa for patients with motor fluctuations. The product is administered once daily and does not require titration in the approved regimen [1].

Rasagiline is metabolized primarily through CYP1A2. The prescribing information restricts use with meperidine, tramadol, methadone, propoxyphene, dextromethorphan and other monoamine oxidase inhibitors because of potential serious central nervous system and cardiovascular reactions. Ciprofloxacin and other CYP1A2 inhibitors can increase rasagiline exposure [1].

What clinical trials established rasagiline's efficacy?

Rasagiline's pivotal evidence supports symptomatic improvement in motor function and reduction of off-time, rather than confirmed neuroprotection.

TEMPO and PRESTO trials

The TEMPO trial evaluated rasagiline in early Parkinson's disease. Patients receiving 1 mg or 2 mg daily had better Unified Parkinson's Disease Rating Scale outcomes than placebo over the treatment period [2].

The PRESTO trial studied patients with Parkinson's disease who had motor fluctuations while receiving levodopa. Rasagiline reduced daily off-time, with the 1 mg dose producing a clinically relevant improvement compared with placebo [3].

LARGO trial

The LARGO trial compared rasagiline with placebo and entacapone as adjunctive therapy to levodopa. Rasagiline 1 mg reduced daily off-time and improved motor symptoms. The study supported rasagiline as a levodopa adjunct but did not establish superiority over entacapone across all clinical measures [4].

ADAGIO disease-modification trial

The ADAGIO trial tested whether early initiation of rasagiline could slow Parkinson's disease progression. The trial used a delayed-start design with 1 mg and 2 mg doses.

The 1 mg group met some prespecified outcomes, but the 2 mg group did not meet the primary endpoint. The overall dataset did not provide a clear regulatory basis for a disease-modifying indication. Rasagiline remains approved for symptomatic treatment, not for slowing underlying neurodegeneration [5].

Are new rasagiline clinical trials still active?

Rasagiline has limited standalone late-stage development activity because its composition and core symptomatic indications are mature. Current research relevance is concentrated in combination therapy, earlier disease, biomarker-driven Parkinson's studies and comparative treatment strategies.

Clinical development status by research area

Research area Status and commercial relevance
Monotherapy in early Parkinson's disease Established indication; limited differentiation
Adjunct to levodopa Established indication; remains the principal use case
Disease modification Unconfirmed after ADAGIO
Cognitive impairment in Parkinson's disease No established rasagiline indication
Dyskinesia reduction May improve motor fluctuation burden, but not a stand-alone dyskinesia product
Combination with other antiparkinsonian drugs Clinically relevant but generally commercially difficult because generic rasagiline is available
Neuroprotection and biomarkers Research interest remains, with no approved claim
New delivery systems Potentially differentiating, but no major FDA-approved reformulation has displaced tablets

ClinicalTrials.gov should be used for a live trial-by-trial status review because Parkinson's disease studies can change status after registry updates. Rasagiline's commercially material clinical position remains its approved use with levodopa rather than a new indication [6].

What patents protect rasagiline and Azilect?

The principal rasagiline composition and formulation patents have expired or reached the end of their effective exclusivity periods in the United States. The original U.S. compound patent did not provide current generic protection.

Patent or protection category Subject matter Commercial significance
U.S. Patent No. 5,532,415 Rasagiline compound and related chemical subject matter Expired; no current U.S. composition exclusivity
U.S. Patent No. 6,316,023 Pharmaceutical compositions and use-related subject matter Expired; historical barrier to generic entry
Orange Book-listed patents Product-specific patents for Azilect Historical basis for patent certification and litigation analysis
Pediatric exclusivity Regulatory extension, if granted Does not create a new composition patent
Data exclusivity New drug approval protection Expired for the original 2006 approval

Patent term depends on filing date, patent-term adjustment, terminal disclaimers and applicable regulatory extensions. The FDA Orange Book and USPTO records provide the controlling source for current listing and expiration analysis [7,8].

Rasagiline's core intellectual-property estate is weak for a U.S. product seeking premium pricing. Potentially defensible areas include crystalline forms, impurities, manufacturing processes, combination products, modified-release systems and specific therapeutic methods. Those rights require separate claim-level review and do not automatically block an ordinary immediate-release generic tablet.

When does rasagiline lose exclusivity?

Rasagiline lost practical U.S. small-molecule exclusivity before the current period. FDA-approved generic rasagiline products entered the U.S. market in the late 2010s, and the commercial market is now driven mainly by generic pricing, formulary placement and supply reliability.

The relevant exclusivity sequence was:

Milestone Approximate timing
Azilect U.S. approval 2006
Core compound patent expiration 2012
Historical formulation and use-patent period Through the late 2010s, depending on patent and adjustment
Generic U.S. entry 2017 onward
Current status Generic competition; no meaningful brand monopoly

A generic applicant generally must address listed patents through a Paragraph III certification, Paragraph IV certification or a statement that no relevant patent is listed. A Paragraph IV filing alleges that a listed patent is invalid, unenforceable or not infringed [9].

What is the FDA and Orange Book status of rasagiline?

Azilect is an FDA-approved prescription drug, while multiple generic rasagiline tablets have been approved through abbreviated new drug applications.

FDA regulatory position

The regulatory profile is mature:

  • The active ingredient is rasagiline mesylate.
  • The reference listed drug is Azilect.
  • Approved strengths include 0.5 mg and 1 mg.
  • The primary dosage form is an immediate-release oral tablet.
  • Generic products must demonstrate pharmaceutical equivalence and bioequivalence to the reference product.
  • No biosimilar pathway applies because rasagiline is a chemically synthesized small molecule, not a biologic.

FDA's Orange Book identifies approved products, therapeutic equivalence information and listed patent data. Patent listings can change, so the current FDA database should control any transaction, launch or litigation decision [7].

Which companies are challenging or competing with Azilect?

The competitive landscape has two tiers: generic rasagiline suppliers and branded or specialty Parkinson's disease products.

Generic rasagiline companies

U.S. generic competition has included major and specialty manufacturers such as Teva, Mylan/Viatris, Apotex, Zydus and other ANDA holders, subject to product availability and market withdrawals. The number of active suppliers can differ from the number of approved ANDAs because manufacturers may discontinue products or maintain limited distribution.

Branded therapeutic competitors

Product Company or originator Mechanism Competitive position
Azilect Teva/Lundbeck heritage MAO-B inhibitor Original rasagiline brand; largely displaced by generics
Eldepryl/Zelapar Selegiline originators and generics MAO-B inhibitor Older class competitor; different dosage forms and interaction profile
Xadago Zambon MAO-B inhibitor with additional pharmacology Branded alternative for adjunctive treatment
Entacapone products Multiple manufacturers COMT inhibitor Competes for levodopa adjunct use
Rytary Amneal Extended-release carbidopa/levodopa Competes through levodopa delivery rather than MAO-B inhibition
Gocovri Adamas/previously Supernus Amantadine extended release Targets dyskinesia and off episodes
Nourianz Kyowa Kirin Adenosine A2A antagonist Adjunctive therapy for off episodes

Rasagiline's main disadvantage against branded alternatives is limited differentiation. Its advantages are once-daily dosing, established evidence, generic availability and generally lower cost.

What patent litigation affected rasagiline generic entry?

Rasagiline's generic-entry disputes centered on the validity, enforceability and scope of Azilect's listed patents. The relevant litigation period was primarily before broad generic commercialization.

Generic applicants using Paragraph IV certifications could trigger the 30-month stay under the Hatch-Waxman framework if the brand holder filed an infringement action within the statutory period. Generic entry could then occur upon patent expiration, settlement terms, court judgment or FDA approval after resolution of the stay.

The commercial consequence was more important than the litigation itself: once the core patent barriers expired, rasagiline became a conventional generic product. No current U.S. litigation appears to restore broad exclusivity for the original molecule or immediate-release tablet.

Settlement agreements and launch timing

Historical settlement terms involving generic applicants can affect the earliest launch date, authorized-generic strategy and damages exposure. Such agreements require review through court dockets, FTC submissions and FDA approval records. A generic settlement does not necessarily imply that all patents were valid; it can reflect the cost and timing of litigation, supply arrangements or an agreed entry date.

How strong is the rasagiline patent estate?

The patent estate is weak for the original immediate-release product and potentially stronger for differentiated delivery or combination technology.

IP segment Strength Reason
Core rasagiline molecule Low Foundational patents expired
Immediate-release 0.5 mg and 1 mg tablets Low Generic products are approved
Approved monotherapy method Low Long-established use and generic substitution
Adjunctive levodopa method Low to moderate Clinical use is established, but broad claims face prior-art pressure
New formulation Moderate if claims are technically narrow Protection depends on formulation novelty and enablement
Manufacturing process Moderate in selected jurisdictions Process claims can matter if difficult to design around
Combination therapy Moderate Value depends on clinical benefit and claim scope
Disease-modifying claim Low regulatory value ADAGIO did not establish the required clinical basis

A licensing or acquisition decision should focus on claim breadth, remaining patent term, freedom to operate, process reproducibility and evidence of clinical differentiation. A patent on a specific formulation does not block an ordinary generic rasagiline tablet unless the generic product practices the asserted claims.

What formulations are protected by rasagiline patents?

The commercial reference product is an immediate-release tablet. Potential formulation claims can cover:

  • Specific salt forms.
  • Particle size or polymorph characteristics.
  • Excipients and dissolution profiles.
  • Oral disintegrating tablets.
  • Modified-release tablets.
  • Combination tablets with levodopa, carbidopa or other Parkinson's medicines.
  • Stabilized formulations with defined impurity limits.
  • Manufacturing processes that control stereochemical purity or degradation products.

The technical opportunity is limited by the drug's low daily dose and established oral administration. A new formulation needs a measurable clinical or commercial advantage, such as improved adherence, reduced interaction risk, easier administration in dysphagic patients or combination-product convenience.

What generic entry risks exist for rasagiline?

Generic entry risk is high in the United States and other mature markets. The principal risks are commercial rather than legal.

U.S. launch scenarios

Scenario Probability profile Market effect
Several generic suppliers remain active Base case Continued price erosion and low brand share
Supplier consolidation or shortage Intermittent risk Temporary price increases and pharmacy substitution shifts
New branded formulation launches Low to moderate Possible niche premium if clinically differentiated
Generic combination product launches Moderate technical interest Could improve convenience but faces reimbursement pressure
New disease-modifying evidence emerges Low based on current evidence Would require a new indication and separate clinical program

A generic manufacturer may face limited profitability because rasagiline has a small market, low tablet volume and multiple approved competitors. Supply interruptions can create temporary share gains, but they are not a durable basis for a branded investment thesis.

How large is the rasagiline market?

Public market reports often combine rasagiline with the broader Parkinson's disease drug market, making rasagiline-only revenue figures difficult to validate. The product's U.S. revenue has declined sharply from the branded Azilect period because of generic substitution.

Market drivers

The demand base is supported by:

  • Growth in the diagnosed Parkinson's disease population.
  • Longer treatment duration.
  • Use as an adjunct to levodopa.
  • Low-cost access in generic markets.
  • Continued use in countries where rasagiline remains routinely prescribed.

The market is constrained by:

  • Generic price erosion.
  • Competition from safinamide and selegiline.
  • Broad use of levodopa optimization strategies.
  • Limited evidence for disease modification.
  • Absence of a major new formulation with a clear clinical advantage.

2025-2030 market projection

The following projection applies to global rasagiline product revenue, including brand and generic sales, rather than the entire Parkinson's disease market. It is a scenario model using a low-single-digit volume growth assumption from Parkinson's disease prevalence and a higher negative net-price trend from generic competition.

Year Low case Base case High case
2025 $180 million $240 million $320 million
2026 $172 million $233 million $314 million
2027 $164 million $226 million $308 million
2028 $157 million $219 million $302 million
2029 $150 million $213 million $296 million
2030 $144 million $207 million $290 million
2025-2030 CAGR -4.4% -3.0% -2.0%

The base case assumes stable prescription volume, continued generic substitution and no approved premium formulation. The high case assumes stronger diagnosis and treatment persistence in emerging markets, while the low case assumes further price compression and substitution by other adjunctive therapies.

The addressable opportunity is larger in units than in revenue. Rasagiline can maintain or increase tablet volume while total sales decline because generic net prices fall faster than demand grows.

How does rasagiline compare with safinamide?

Rasagiline and safinamide both support adjunctive treatment in Parkinson's disease, but their commercial profiles differ.

Factor Rasagiline Safinamide
Mechanism Selective MAO-B inhibition MAO-B inhibition with additional sodium-channel and glutamate-related effects
Dosing Once daily Once daily
U.S. status Generic and brand history Branded product
Price position Low Premium
Evidence base Established monotherapy and adjunct use Primarily adjunctive use with levodopa
Patent value Core estate expired Newer product estate, subject to patent review
Commercial risk Price erosion Reimbursement and patent exposure
Main differentiation Familiarity, low cost, long clinical history Branded differentiation and later-generation positioning

Rasagiline is more attractive for volume-based generic strategies. Safinamide is more attractive for a branded strategy only if clinical outcomes, payer access and patent duration support the premium.

What licensing and partnering opportunities exist for rasagiline?

The most credible licensing opportunities involve delivery, combination therapy and geographic commercialization rather than the original molecule.

Potential transaction targets include:

  1. Regional rights in markets where rasagiline remains underpenetrated.
  2. Fixed-dose combinations with carbidopa/levodopa.
  3. Orally disintegrating or swallow-friendly formulations.
  4. Manufacturing technology that lowers impurity levels or improves yield.
  5. Specialty generic distribution through neurology-focused channels.
  6. Combination development with therapies targeting dyskinesia or motor fluctuations.

A license for ordinary rasagiline tablets is unlikely to command a substantial premium unless it includes protected territory, a reliable supply advantage or a differentiated formulation. Product rights should be valued against generic net pricing, regulatory filing costs, manufacturing redundancy and expected formulary substitution.

What geographic markets are most relevant?

Rasagiline has broad international regulatory exposure, but market value varies substantially by patent status, reimbursement and generic penetration.

United States

The U.S. market is mature and generic. The primary opportunities are supply reliability, contract manufacturing, specialty pharmacy distribution and niche dosage forms.

Europe

European markets are fragmented by national reimbursement systems and tendering. Generic substitution is extensive, while neurologist prescribing patterns vary by country. Local marketing authorization, pharmacovigilance and tender access are more important than broad patent exclusivity.

China and other Asian markets

Diagnosis rates, specialist access and treatment penetration can support volume growth. Price controls and local generic competition limit revenue per patient. Local manufacturing and registration strategy can materially affect market share.

Latin America and other emerging markets

The opportunity is volume-led. Distribution, registration, import requirements and affordability determine commercial performance. A low-cost, stable-supply product can compete effectively without a differentiated patent estate.

What manufacturing and intellectual-property barriers remain?

Rasagiline synthesis requires control of stereochemistry, impurity profile and batch consistency. The molecule's commercial manufacturing barriers are manageable for experienced generic manufacturers, but regulatory execution remains important.

Key technical risks include:

  • Control of the R-enantiomer and unwanted stereoisomers.
  • Residual solvent and process impurity limits.
  • Stability of the mesylate salt.
  • Tablet dissolution and content uniformity.
  • Consistent low-dose manufacturing.
  • Demonstration of bioequivalence.
  • Supply continuity for active pharmaceutical ingredient.

Manufacturing-process patents can create jurisdiction-specific barriers even when composition patents have expired. A design-around process may reduce legal exposure but increase validation cost or impurity risk.

Key Takeaways

  • Rasagiline is an established symptomatic treatment for Parkinson's disease, used alone in early disease and with levodopa in motor fluctuations.
  • TEMPO, PRESTO and LARGO established efficacy for motor symptoms and off-time reduction.
  • ADAGIO did not establish a disease-modifying indication.
  • U.S. exclusivity has ended, and the market is generic-dominated.
  • The core rasagiline patent estate has limited current blocking power.
  • Paragraph IV litigation was primarily relevant before generic commercialization.
  • No biosimilar pathway applies; rasagiline is a small-molecule generic product.
  • The base-case global rasagiline market is projected to decline from about $240 million in 2025 to $207 million in 2030 as price erosion exceeds volume growth.
  • Commercial upside is concentrated in formulations, combinations, emerging markets and reliable generic supply.
  • A branded investment requires a clinically meaningful delivery or combination advantage, not merely a new trade name.

FAQs about rasagiline patents, trials and market outlook

Is rasagiline still commercially relevant after generic entry?

Yes. It remains clinically relevant as a low-cost once-daily adjunct to levodopa, although generic competition has sharply reduced revenue per prescription.

Does rasagiline slow Parkinson's disease progression?

No disease-modifying benefit has been established for regulatory purposes. The ADAGIO trial produced mixed results and did not support a disease-modifying indication.

Can a company obtain new patents on rasagiline?

Potentially. New patents may cover formulations, combinations, manufacturing processes or narrowly defined methods. A new patent would not automatically block existing immediate-release generics.

Is rasagiline a substitute for levodopa?

No. Rasagiline is commonly used as monotherapy in selected early patients or as an adjunct to levodopa. It does not replace levodopa for patients who require stronger symptomatic control.

What is the most attractive rasagiline investment strategy?

A differentiated product with enforceable formulation or combination claims is more attractive than an ordinary tablet. Generic strategies depend on manufacturing cost, supply reliability, tender access and geographic scale.

References

  1. U.S. Food and Drug Administration. (2020). Azilect (rasagiline mesylate) prescribing information. FDA.

  2. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: The TEMPO study. Archives of Neurology, 59(12), 1937-1943.

  3. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Archives of Neurology, 62(2), 241-248.

  4. Rascol, O., Barone, P., Hauser, R. A., Mizuno, Y., Salin, L., Sohr, M., Debieuvre, C., & LARGO Study Group. (2005). A double-blind, placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The LARGO study. Archives of Neurology, 62(2), 241-248.

  5. Olanow, C. W., Rascol, O., Hauser, R., Feigin, A., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., Tolosa, E., & ADAGIO Study Investigators. (2009). A double-blind, delayed-start trial of rasagiline in Parkinson's disease. New England Journal of Medicine, 361(13), 1268-1278.

  6. National Library of Medicine. (n.d.). ClinicalTrials.gov: Rasagiline studies. U.S. National Library of Medicine.

  7. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

  8. United States Patent and Trademark Office. (n.d.). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 5,532,415 and 6,316,023. USPTO.

  9. U.S. Food and Drug Administration. (2017). Guidance for industry: 180-day exclusivity when multiple ANDA applicants are eligible for 180-day exclusivity. FDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.